================================================================================
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
--------------------------------------------------------------------------------
FORM 8-K
--------------------------------------------------------------------------------
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): February 7, 2008
Pharmion Corporation
(Exact name of Registrant as specified in its charter)
Delaware 000-50447 84-1521333
(State or other jurisdiction of (Commission File Number) (IRS Employer
incorporation) Identification
No.)
2525 28th Street, Boulder, Colorado 80301
(Address of principal executive offices) (Zip Code)
720-564-9100
(Registrant's telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the Registrant under any of the
following provisions (see General Instruction A.2 below):
[ ] Written communications pursuant to Rule 425 under the Securities Act
(17 CFR 230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17
CFR 240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the
Exchange Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240.13e-4(c))
================================================================================
Item 8.01 Other Events.
On February 7, 2008, Pharmion Corporation ("Pharmion" or the "Company")
announced that the European Medicines Agency has accepted for review the
Company's Marketing Authorization Application for Vidaza (R) (azacitidine for
injection) in patients with higher-risk myelodysplastic syndromes and announced
its intent to review the application under the Accelerated Assessment Procedure.
The press release is attached hereto as an exhibit and is incorporated by
reference herein.
Item 9.01 Financial Statements and Exhibits.
(d)
Exhibit 99.1 Press Release issued by Pharmion Corporation, dated
February 7, 2008
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended,
the Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
Date: February 7, 2008 PHARMION CORPORATION
By: /s/ Steven N. Dupont
------------------------------
Name: Steven N. Dupont
Title: Executive Vice President
and General Counsel
EXHIBIT INDEX
Exhibit No. Description
----------- -----------
Exhibit 99.1 Press Release issued by Pharmion Corporation, dated
February 7, 2008